Madera et al. developed another ADC targeting GPC3 composed of a humanized IgG1 antibody conjugated to a topoisomerase 1 inhibitor, ZW251, with evidence of potent and target-specific cytotoxicity in a panel of HCC cells, as well as robust tumor growth inhibition after a single administration in several cell-line derived and patient-derived xenograft murine models representing a wide-range of GPC3 expression [108]. This evidence concerns the gene GPC3 and neoplasm.